发现了一种具有改善体内药动力学特征和验证向作用的小分子TREM2激活剂
Shaoren Yuan1, Farida El Gaamouch1, Sungwoo Cho1
1Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, New York 10065, United States.
ACS medicinal chemistry letters
|August 20, 2025
概括
研究人员发现了C1,一种用于阿尔茨海默病的新型TREM2激应剂. C1 增强了微细胞分裂,并显示出改善的药物动力学特性,使其成为有前途的治疗.
科学领域:
- 神经科学
- 药理学
- 医学化学
背景情况:
- 在骨髓细胞2 (TREM2) 上表达的触发受体是微质功能的关键调节者,也是阿尔茨海默病 (AD) 的重要治疗点.
- 现有的TREM2激动剂,如VG-3927,具有治疗潜力,但可能会从改善的药理特性中受益.
研究的目的:
- 发现和描述TREM2激发剂VG-3927的新型结构简化的类似物C1.
- 评估C1在增强微质功能的有效性及其潜在的AD治疗药物的药理动力学特征.
主要方法:
- 使用模块化,无酶选择性路径合成C1,涉及顺序的苏兹基合.
- 在基于细胞的测试中评估C1对微细胞和TREM2信号激活的影响 (HEK293-hTREM2/DAP12).
- 使用表面等离子体共振 (SPR) 和微尺度热泳 (MST) 确认直接的TREM2结合.
- 评估体外的药物动力学特性,包括代谢稳定性,被动透性 (PAMPA) 和中枢神经系统透性 (日志D7.4).
主要成果:
- C1的合成效率高,使得脚手架的多样化迅速.
- 与VG-3927相比,C1表现出较高的微细胞和TREM2信号激活.
- 通过SPR和MST确认了C1与TREM2的直接结合.
- 与VG-3927相比,C1表现出更强的代谢稳定性,有利的被动透性和与中枢神经系统兼容的D7.4日志,这表明其药物动力学特征得到了改善.
结论:
- C1是VG-3927的可访问,立体化学简化的模拟物,具有验证的TREM2目标接触.
- C1具有卓越的体外疗效和药物动力学特性,使其成为开发新型TREM2向阿尔茨海默病治疗的有前途的领先化合物.
相关概念视频
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Pharmacodynamics: Overview and Principles
2.0K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.0K


